http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 08:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Press+Releases/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html <p> <i>Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological intelligence infrastructure behind that record drives the Company&apos;s work today.</i> </p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <b>MindWalk Holdings Corp. (NASDAQ: HYFT) </b>today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, http://www.streetinsider.com/Business+Wire/The+Biology+Came+First./26510813.html Mon, 18 May 2026 08:34:00 -0400 0QW0 A.02264286 A.03302840 A.15343852 ARGX CGEM HYFT IDXX IPA O.00017340 O.00222364 O.00338863 O.02598349 O.03259153 O.04870500 O.29492292 O.49467714 XNCR